30–70 50–75% of normal dose10–30 50–75% of normal dose. Use with care
<10           : 50% of normal dose. Use with care
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR=10–30 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosisCytotoxics: increased pulmonary toxicity with pentostatin (unacceptably high incidence of fatalities); increases intracellular concentration of cytarabine
ADMINISTRATION
Reconstition
Reconstitute each vial with 2 mL of water to give a concentration of 25 mg/mL
Route
IV, oral
Rate of Administration
Infusion should be administered over 30 minutes
Comments
IV bolus in 10 mL of sodium chloride 0.9%
IV infusion
in 100 mL of sodium chloride 0.9%
OTHER INFORMATION
Rapidly dephosphorylated in plasma to (2-F-9-ß-D-arabinofuranosyladenine) 2-F-ara-ATP, which is necessary for cellular uptakeApproximately 60% of an administered dose is excreted in the urine within 24 hrsAdminister up to achievement of clinical response (usually 6 cycles) then discontinuePatients with renal failure (GFR=17– 41 mL/min/m2) receiving 20% of dose had a similar AUC as patients with normal renal function receiving the full doseFludarabine phosphate.